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Lysosomal acid lipase in cancer
Cong Yan, Ting Zhao and Hong Du
Lysosomal Acid Lipase Regulates Myeloid-derived 
Suppressor Cells to Control Cancer Cell Proliferation 
and Metastasis. Inflammation critically contributes to 
cancer growth and metastasis, in which myeloid-derived 
suppressor cells (MDSCs) are an important participant. 
MDSCs are known to suppress immune surveillance to 
promote tumorigenesis [1]. Lysosomal acid lipase (LAL), 
a critical enzyme in controlling neutral lipid metabolic 
signaling, hydrolyzes cholesteryl esters and triglycerides 
in the lysosome of cells to generate free fatty acids and 
cholesterol. Deficiency of this metabolic enzyme causes 
abnormal hematopoietic development, skewing progenitor 
cell differentiation towards an overabundance of myeloid 
cells in the bone marrow. As a result, immature MDSCs 
expand dramatically and accumulate in the bone marrow, 
peripheral blood, immune organs (e.g. thymus, spleen) 
and distal organs (e.g. lung, liver) [2]. Systemic infiltration 
of lal-/- MDSCs is facilitated by changed ECs functions 
through various mechanisms. lal-/- MDSCs promote ECs 
angiogenesis, tube formation, and proliferation [3].
Upon exiting the bone marrow and entering 
circulation and distal organ compartments, lal-/- MDSCs 
promote tumorigenesis by two mechanisms. First, 
infiltration of lal-/- MDSCs leads to abnormal organization 
of the thymus and spleen, impair progression of T cell 
development in the thymus, and retard T cell maturation 
in the spleen. In the blood and distal organs, lal-/- MDSCs 
strongly suppress peripheral T cell proliferation and 
lymphokine release [4]. This is largely due to increased 
apoptosis and decreased proliferation of lal-/- T cells in 
thymus and peripheral compartments. As a consequence, 
the anti-tumor immunity is significantly weakened. 
Second, lal-/- MDSCs directly stimulate tumor cell 
proliferation, growth and metastasis even in an allogenic 
mouse model, showing that lal-/- MDSCs are able to 
overcome host immune rejection [5]. Therefore, MDSCs 
facilitate tumorigenesis at least by two mechanisms: 
1) suppressing immune surveillance; and 2) stimulating 
cancer cell proliferation, growth and metastasis directly.
Based on Affymetrix GeneChip microarray and 
Ingenuity Pathway analyses, the mammalian target 
of rapamycin (mTOR) signaling and peroxisome 
proliferator-activated receptor gamma (PPARγ) signaling 
are two major pathways that mediate pathogenic 
phenotypes of lal-/- MDSCs in suppressing immune 
surveillance and stimulating tumorigenesis [6]. These 
activities are associated with alteration of other genes 
involved in cell growth, cell cycle entry, cell survival, 
cell migration, histone epigenetics, bioenergetic 
pathways, and ROS production [6]. Inhibition of mTOR 
by pharmacological inhibitors and siRNA interference 
not only reduces immunosuppressive function of lal-/- 
MDSCs, but also suppresses their stimulation on tumor 
proliferation, progression and metastasis [5, 7]. mTOR 
inhibitor treatment of lal-/- mice reverses the increased 
proliferation, decreased apoptosis, increased ATP 
synthesis, and increased cell cycling in lal-/- MDSCs. 
Pharmacological and siRNA suppression of mTOR, 
Raptor, Rictor, and Akt1 also correct lal-/- MDSCs 
development from Lin- progenitor cells, decrease ROS 
production, and recover from impairment of mitochondrial 
membrane potential.
On the other hand, derivatives of free fatty acid 
metabolites serve as hormonal ligands for nuclear receptors 
(e.g. PPARγ) that possess the anti-inflammatory function. 
Myeloid-specific expression of human LAL (hLAL) 
to restore the PPARγ function in lal-/- mice reverses 
both immunosuppression and tumor stimulation [2, 5]. 
Reintroducing PPARγ ligands into lal-/- mice also reverses 
immunosuppression and tumor stimulation (unpublished 
result). To confirm the functional role of PPARγ in 
myeloid cells, dominant negative PPARγ (dnPPARγ) was 
overexpressed in a myeloid-specific bitransgenic mouse 
model [8]. Overexpression of dnPPARγ in myeloid lineage 
cells abnormally elevates frequencies and total numbers 
of LK, LSK, CMP and GMP progenitor populations in 
the bone marrow. As a result, MDSCs are systemically 
increased in association with activation of Stat3, NF-kB, 
Erk1/2 and p38 molecules. MDSCs from this system 
inhibit the proliferation and lymphokine production 
of T cells. Both CD4+ and CD8+ T cell populations are 
decreased in conditional bitransgenic mice. Multiple forms 
of carcinoma and sarcoma in the lung, liver, spleen and 
lymph nodes are observed. Bone marrow transplantation 
reveals that a myeloid autonomous defect is responsible 
for MDSCs expansion, immunosuppression and 
tumorigenesis in this conditional bitransgenic model [8]. 
Therefore, the metabolic signaling controlled by the LAL/
PPARγ/mTOR axis is essential for MDSCs development, 
homeostasis and functions during tumorigenesis, which 
Oncoscience 2015, Vol.2, No.9
Editorial
Oncoscience728www.impactjournals.com/oncoscience
can facilitates pharmacological drug and immunotherapy 
designs in clinical application.
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